|
1
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar
|
|
2
|
David MR: The epidemiology of gastric
cancer. Gastric Cancer. 5:5–11. 2002. View Article : Google Scholar
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
4
|
Flegal KM, Carroll MD, Kit BK and Ogden
CL: Prevalence of obesity and trends in the distribution of body
mass index among US adults, 1999–2010. JAMA. 307:491–497. 2012.
|
|
5
|
El-Serag HB: Obesity and disease of the
esophagus and colon. Gastroenterol Clin North Am. 34:63–82. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Whiteman MK, Hillis SD, Curtis KM,
McDonald JA, Wingo PA and Marchbanks PA: Body mass and mortality
after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev.
14:2009–2014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.
|
|
8
|
Yang P, Zhou Y, Chen B, Wan HW, Jia GQ,
Bai HL and Wu XT: Overweight, obesity and gastric cancer risk:
results from a meta-analysis of cohort studies. Eur J Cancer.
45:2867–2873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Daquinag A, Traktuev DO, et al:
White adipose tissue cells are recruited by experimental tumors and
promote cancer progression in mouse models. Cancer Res.
69:5259–5266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samal B, Sun Y, Stearns G, Xie C, Suggs S
and McNiece I: Cloning and characterization of the cDNA encoding a
novel human pre-B-cell colony-enhancing factor. Mol Cell Biol.
14:1431–1437. 1994.PubMed/NCBI
|
|
11
|
Fukuhara A, Matsuda M, Nishizawa M, et al:
Visfatin: a protein secreted by visceral fat that mimics the
effects of insulin. Science. 307:426–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bi TQ and Che XM: Nampt/PBEF/visfatin and
cancer. Cancer Biol Ther. 10:119–125. 2010. View Article : Google Scholar
|
|
13
|
Van Beijnum JR, Moerkerk PT, Gerbers AJ,
De Bruïne AP, Arends JW, Hoogenboom HR and Hufton SE: Target
validation for genomics using peptide-specific phage antibodies: a
study of five gene products overexpressed in colorectal cancer. Int
J Cancer. 101:118–127. 2002.PubMed/NCBI
|
|
14
|
Folgueira MA, Carraro DM, Brentani H, et
al: Gene expression profile associated with response to
doxorubicin-based therapy in breast cancer. Clin Cancer Res.
11:7434–7443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL,
Li HJ and Zhao W: Overexpression of Nampt in gastric cancer and
chemopotentiating effects of the Nampt inhibitor FK866 in
combination with fluorouracil. Oncol Rep. 26:1251–1257.
2011.PubMed/NCBI
|
|
16
|
Revollo JR, Grimm AA and Imai S: The
regulation of nicotinamide adenine dinucleotide biosynthesis by
Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol.
23:164–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Voelter-Mahlknecht S and Mahlknecht U:
Cloning, chromosomal characterization and mapping of the
NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med.
17:59–67. 2006.PubMed/NCBI
|
|
18
|
Luo J, Nikolaev AY, Imai S, et al:
Negative control of p53 by Sir2alpha promotes cell survival under
stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vaziri H, Dessain SK, Ng Eaton E, et al:
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell.
107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuzmichev A, Margueron R, Vaquero A, et
al: Composition and histone substrates of polycomb repressive group
complexes change during cellular differentiation. Proc Natl Acad
Sci USA. 102:1859–1864. 2005.PubMed/NCBI
|
|
21
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saunders LR and Verdin E: Sirtuins:
critical regulators at the crossroads between cancer and aging.
Oncogene. 26:5489–5504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim CS: Human SIRT1: a potential biomarker
for tumorigenesis? Cell Biol Int. 31:636–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lüscher B and Vervoorts J: Regulation of
gene transcription by the oncoprotein MYC. Gene. 494:145–160.
2012.PubMed/NCBI
|
|
25
|
Eilers M and Eisenman RN: Myc's broad
reach. Genes Dev. 22:2755–2766. 2008.
|
|
26
|
Soucek L, Whitfield J, Martins CP, et al:
Modelling Myc inhibition as a cancer therapy. Nature. 455:679–683.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Menssen A, Hydbring P, Kapelle K, et al:
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1,
and the SIRT1 deacetylase form a positive feedback loop. Proc Natl
Acad Sci USA. 109:E187–E196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li HJ, Che XM, Zhao W, He SC, Zhang ZL and
Chen R: Diet-induced obesity potentiates the growth of gastric
cancer in mice. Exp Ther Med. 4:615–620. 2012.PubMed/NCBI
|
|
29
|
Qian SS, Gao J, Wang JX, Liu Y and Dong
HY: Establishment of a mouse forestomach carcinoma cell line (MFC)
with spontaneous hematogenous metastasis and preliminary study of
its biological characteristics. Zhonghua Zhong Liu Za Zhi.
9:261–264. 1987.(In Chinese).
|
|
30
|
Yakar S, Nunez NP, Pennisi P, et al:
Increased tumor growth in mice with diet-induced obesity: impact of
ovarian hormones. Endocrinology. 147:5826–5834. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vermes I, Haanen C, Steffens-Nakken H and
Reutelingsperger C: A novel assay for apoptosis. Flow cytometric
detection of phosphatidylserine expression on early apoptotic cells
using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
1995. View Article : Google Scholar
|
|
32
|
Iyengar P, Combs TP, Shah SJ, et al:
Adipocyte-secreted factors synergistically promote mammary
tumorigenesis through induction of anti-apoptotic transcriptional
programs and proto-oncogene stabilization. Oncogene. 22:6408–6423.
2003. View Article : Google Scholar
|
|
33
|
Amemori S, Ootani A, Aoki S, et al:
Adipocytes and preadipocytes promote the proliferation of colon
cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol.
292:G923–G929. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caers J, Deleu S, Belaid Z, et al:
Neighboring adipocytes participate in the bone marrow
microenvironment of multiple myeloma cells. Leukemia. 21:1580–1584.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tilg H and Moschen AR: Adipocytokines:
mediators linking adipose tissue, inflammation and immunity. Nat
Rev Immunol. 6:772–783. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim SR, Park HJ, Bae YH, et al: Curcumin
down-regulates visfatin expression and inhibits breast cancer cell
invasion. Endocrinology. 153:554–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim JG, Kim EO, Jeong BR, et al: Visfatin
stimulates proliferation of MCF-7 human breast cancer cells. Mol
Cells. 30:341–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Patel ST, Mistry T, Brown JE, Digby JE,
Adya R, Desai KM and Randeva HS: A novel role for the adipokine
visfatin/pre-B cell colony-enhancing factor 1 in prostate
carcinogenesis. Peptides. 31:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reddy PS, Umesh S, Thota B, et al:
PBEF1/NAmPRTase/Visfatin: a potential malignant
astrocytoma/glioblastoma serum marker with prognostic value. Cancer
Biol Ther. 7:663–668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakajima TE, Yamada Y, Hamano T, et al:
Adipocytokine levels in gastric cancer patients: resistin and
visfatin as biomarkers of gastric cancer. J Gastroenterol.
44:685–690. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nakajima TE, Yamada Y, Hamano T, et al:
Adipocytokines as new promising markers of colorectal tumors:
adiponectin for colorectal adenoma, and resistin and visfatin for
colorectal cancer. Cancer Sci. 101:1286–1291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Garten A, Petzold S, Körner A, Imai S and
Kiess W: Nampt: linking NAD biology, metabolism and cancer. Trends
Endocrinol Metab. 20:130–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pilz S, Mangge H, Obermayer-Pietsch B and
März W: Visfatin/pre-B-cell colony-enhancing factor: a protein with
various suggested functions. J Endocrinol Invest. 30:138–144. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sciacca L, Costantino A, Pandini G, et al:
Insulin receptor activation by IGF-II in breast cancers: evidence
for a new autocrine/paracrine mechanism. Oncogene. 18:2471–2479.
1998. View Article : Google Scholar : PubMed/NCBI
|
